Joshua Sznol, MD, MSPH
Hospital Resident
Research & Publications
Biography
Coauthors
Selected Publications
- Routine post-operative labs and healthcare system burden in acute appendicitisSznol J, Becher R, Maung A, Bhattacharya B, Davis K, Schuster K. Routine post-operative labs and healthcare system burden in acute appendicitis. The American Journal Of Surgery 2023, 226: 571-577. PMID: 37291012, DOI: 10.1016/j.amjsurg.2023.06.005.
- Impact of nonmalignant ascites on outcomes of open inguinal hernia repair in the USAKerekes D, Sznol J, Khan S, Becher R. Impact of nonmalignant ascites on outcomes of open inguinal hernia repair in the USA. Hernia 2023, 27: 1497-1506. PMID: 37029887, DOI: 10.1007/s10029-023-02790-3.
- Management and Outcome of High-Grade Hepatic and Splenic InjuriesPresser E, Sznol J, Schuster K. Management and Outcome of High-Grade Hepatic and Splenic Injuries. Current Surgery Reports 2023, 11: 55-63. DOI: 10.1007/s40137-023-00344-1.
- Complications of 761 Short-term Intrathecal Macrocatheters in Obstetric PatientsCohn J, Moaveni D, Sznol J, Ranasinghe J. Complications of 761 Short-term Intrathecal Macrocatheters in Obstetric Patients. Obstetric Anesthesia Digest 2016, 36: 218-219. DOI: 10.1097/01.aoa.0000504750.10227.0f.
- Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.Kluger H, Halabi S, Solomon N, Jilaveanu L, Zito C, Sznol J, Nixon A, Rini B, Small E, George D. Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206. Journal Of Clinical Oncology 2014, 32: 4532-4532. DOI: 10.1200/jco.2014.32.15_suppl.4532.